Cargando…
The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
Inclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) by ≥50% in patients with hypercholesterolemia receiving maximally tolerated statins. The tox...
Autores principales: | Lehoux, Dario, Kallend, David, Wijngaard, Peter L. J., Brown, Alan P., Zerler, Brad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077952/ https://www.ncbi.nlm.nih.gov/pubmed/37021909 http://dx.doi.org/10.1002/prp2.1080 |
Ejemplares similares
-
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023) -
An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
por: Kallend, David, et al.
Publicado: (2022) -
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023) -
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023) -
Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)